CORT
HealthcareCorcept Therapeutics Incorporated
$34.95
$-3.25 (-8.51%)
Jan 5, 2026
Price History (1Y)
Analysis
Corcept Therapeutics Incorporated is a biotechnology company operating in the healthcare sector. With a market capitalization of $3.68 billion, it has a substantial scale. The company employs approximately 500 individuals and generates revenue of $741.17 million. The company's financial health appears to be relatively stable. It boasts a gross margin of 98.2% and a profit margin of 14.3%. Return on equity stands at 16.7%, while return on assets is 5.1%. The balance sheet shows cash reserves of $421.68 million, with debt amounting to $6.36 million. Valuation metrics suggest that the company is trading at a premium. The price-to-earnings ratio (TTM) stands at 43.69, while the forward P/E is 50.51. Revenue growth has been steady, with a year-over-year increase of 13.7%. However, earnings growth has been negative, with a year-over-year decline of -61.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Visit website →Key Statistics
- Market Cap
- $3.68B
- P/E Ratio
- 43.69
- 52-Week High
- $117.33
- 52-Week Low
- $32.99
- Avg Volume
- 1.32M
- Beta
- 0.23
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 500